Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.390
+0.010 (0.72%)
At close: Feb 6, 2026, 4:00 PM EST
1.400
+0.010 (0.72%)
After-hours: Feb 6, 2026, 7:59 PM EST
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Akebia Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $5.92, which forecasts a 325.90% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $7.50.
Price Target: $5.92 (+325.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +187.77% | Feb 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +331.65% | Feb 6, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +259.71% | Dec 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +331.65% | Dec 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $6 | Strong Buy | Maintains | $8 → $6 | +331.65% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
244.13M
from 160.18M
Increased by 52.41%
Revenue Next Year
296.79M
from 244.13M
Increased by 21.57%
EPS This Year
0.04
from -0.33
EPS Next Year
0.11
from 0.04
Increased by 138.64%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 267.1M | 329.2M | ||||
| Avg | 244.1M | 296.8M | ||||
| Low | 219.5M | 252.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 66.8% | 34.9% | ||||
| Avg | 52.4% | 21.6% | ||||
| Low | 37.0% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.12 | 0.26 | ||||
| Avg | 0.04 | 0.11 | ||||
| Low | -0.03 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 484.9% | ||||
| Avg | - | 138.6% | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.